

Borough Park
1428 36th Street
Suite 107
Brooklyn, NY 11218

Forest Hills
64-05 Yellowstone Blvd
CF104
Forest Hills, NY 11375

Sheepshead Bay
2546 East 17th Street
Fl. 1
Brooklyn, NY 11235

Bronx
226 West 238th Street
Bronx, NY 10463

E 56th & Park Midtown
120 East 56 Street
Suite 300
New York, NY 10022

FIDI
30 Broad Street
Suite 401
New York, NY 10004

Gramercy
7 Gramercy Park West
Lower Level
New York, NY 10003

NYC
E 70th St Upper East Side
225 E 70th Street
Suite 1E
New York, NY 10021

Central Park West
115 Central Park West
Suite 15
New York, NY 10023

ThrIVewell
I N F U S I O N
Office: 212-803-3339 Fax : 646-768-8600


Mission Medical

Tarrytown
555 Taxter Road
3rd Floor
Elmsford, NY 10523

Port Jefferson
12 Medical Drive
Suite B
Port Jefferson Station, NY 11776

Staten Island
27 New Dorp Lane
Staten Island, NY 10306

Southampton
625 Hampton Road
Southampton, NY 11968

Riverhead
1228 E Main Street
Suite A
Riverhead, NY 11901

Holbrook
233 Union Avenue
Suite 207
Holbrook, NY 11741

Manhasset
333 East Shore Road
Suite 201
Manhasset, NY 11030

Rockville Centre
165 North Village Avenue
Suite 133
Rockville Center, NY 11570

New Hyde Park
1991 Marcus Ave
Suite 110
Lake Success, NY 11042

Woodbury
7600 Jericho Tpke,
Lower Level, Suite C500
Woodbury NY 11797

PEMGARDA (pemivibart)

ORDER FORM

Date: _____

PATIENT INFORMATION			
Name:		Phone:	DOB:
SEX: M ☐ F ☐			
☐ NKDA	Allergies:	Weight lbs/kg:	

PHYSICIAN INFORMATION		
Physician Name:		Practice Name:
Address:		Office Contact Name:
Phone:		Office Contact #:
Fax:		Email (for updates):

REFERRAL STATUS	
☐ New Referral	☐ Referral Renewal
☐ Medication/Order Change	☐ Benefits Verification Only
☐ Discontinuation Order	

PEMGARDA: injection, for intravenous use.

The U.S. Food and Drug Administration (FDA) has issued an EUA for the emergency use of the unapproved product PEMGARDA for the pre-exposure prophylaxis of COVID-19 in adults and adolescents (12 years of age and older weighing at least 40 kg):

- Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 **and**
- Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments **and** are unlikely to mount an adequate immune response to COVID-19 vaccination.

☐ **ICD-10*:** _____

☐ **Dx Code:** _____

☐ **Dx Code:** _____

PRE-MEDICATION

☐ Tylenol PO 650mg

☐ 1000mg

☐ other _____

☐ SoluMedrol 125mg IV

☐ other _____

☐ Benadryl

☐ 25mg

☐ 50mg

☐ other _____

☐ IV

☐ PO

☐ Medication _____

Dose _____

Route _____

☐ _____

(other)

☐ _____

(other)

WARNINGS AND PRECAUTIONS

<https://invivyd.com/wp-content/uploads/2024/09/EUA-122-Grant-Revised-FS-for-HCP.pdf>

PEMGARDA ORDERS

PATIENT WEIGHT

_____ lbs.

_____ kg

☐ Initial dosage of PEMGARDA in adults and adolescents (12 years of age and older weighing t least 40 kg) is 4500mg

☐ Repeat 4500mg of PEMGARDA administered every 3 months x _____ doses

• Clinically monitor patients during infusion and observe patients for at least 2 hours after infusion is completed.

NOTES/ADDITIONAL COMMENTS:

REQUIRED DOCUMENTATION CHECKLIST:

_____ Patient Demographics

_____ Insurance Card/Information

_____ Recent Labs

_____ Recent Progress and Vaccination Status

_____ Other

ORDERING PROVIDER

Signature **X** _____

Date _____

Provider _____

Phone _____

Fax _____

Diagnosis Code: _____

Order/dosage: _____

Signature: _____